Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The drugmaker evaluated a post-surgery Herceptin, Perjeta and chemotherapy regimen over ten years in its phase 3 APHINITY study of 4,804 patients. The regimen slashed the risk of death by 17% ...

the risk of death was reduced by 17% for people treated with Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) ...

Treatment with Perjeta, Herceptin and chemotherapy post-surgery led to a significant overall survival benefit in HER2-positive early-stage breast cancer. Treatment with Perjeta (pertuzumab), Herceptin ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer – Long term follow-up in this curative setting ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials ...